Dihexa

Dihexa (also called PNB-0408) is a small peptide-like molecule derived from the C-terminal region of Angiotensin IV. It was developed by Joseph Harding, John Wright, and colleagues at Washington State University, initially as part of an effort to create brain-penetrating analogs of Angiotensin IV that could improve cognitive function in models of Alzheimer's disease and other dementias.

What makes Dihexa exceptional in the nootropic and cognitive research space is the potency claim associated with it. Laboratory research suggests it facilitates synaptogenesis (formation of new synaptic connections) with a potency described as approximately seven orders of magnitude (10 million times) greater than brain-derived neurotrophic factor (BDNF) — the endogenous protein most associated with synaptogenesis and neuroplasticity.

This extraordinary claimed potency, combined with evidence of cognitive enhancement in animal models of neurodegeneration, has generated significant interest in the neuroscience and nootropic communities. However, Dihexa's extreme potency also raises important safety questions about long-term neurological consequences that have not been adequately studied in humans.

Dihexa has not been approved by the FDA, and no human clinical trials have been completed as of 2026. Its use in humans is entirely experimental and potentially carries unknown risks.

Dihexa's mechanism of action centers on HGF/c-Met signaling:

• HGF/c-Met pathway activation: Dihexa binds to and activates the hepatocyte growth factor (HGF) receptor c-Met in neurons. HGF/c-Met signaling is a master regulator of neurodevelopment and neuroplasticity, promoting synaptogenesis, neuronal survival, and axonal sprouting.
• Synaptogenesis: Through c-Met activation, Dihexa promotes the formation of new synaptic connections between neurons, the biological basis of learning, memory consolidation, and cognitive recovery. This synaptogenic activity is the source of its extraordinary potency claims relative to BDNF.
• Angiotensin system interaction: As an Angiotensin IV analog, Dihexa interacts with angiotensin IV receptors (AT4/IRAP), though the exact contribution of this mechanism versus c-Met activation is an area of ongoing research.
• Blood-brain barrier penetration: A key feature of Dihexa over native HGF (a large protein) is its ability to cross the blood-brain barrier — essential for CNS effects when given systemically. This property was engineered into the molecule during development.
• Hippocampal neuroplasticity: Studies have specifically demonstrated effects on hippocampal dendritic spine density and synaptic density, which correlate with improved performance in spatial memory tasks.

Dihexa's potential benefits come primarily from animal studies; no controlled human data exists:

• Cognitive enhancement in impairment models: Animal studies using bilateral hippocampal lesions (models of cognitive impairment) show that Dihexa-treated animals perform equivalent to or better than non-lesioned controls on spatial navigation tasks — a striking degree of cognitive rescue.
• Alzheimer's disease relevance: Models of Alzheimer's disease show improved cognitive function with Dihexa, related to its ability to promote synaptogenesis in regions where synaptic loss is characteristic of the disease.
• Cognitive improvement in healthy subjects (animal): Even in non-impaired animals, Dihexa has been reported to improve performance on learning and memory tasks, suggesting direct cognitive enhancement beyond just neuroprotection.
• Long-lasting effects: Animal data suggests that the cognitive benefits of Dihexa may persist well beyond the period of active administration, possibly because synaptogenesis represents a structural change rather than a transient pharmacological effect.

The striking potency and durability of effects in animal models is compelling, but the translation to human cognition remains entirely hypothetical at this time.

Dihexa's safety profile in humans is essentially unknown, as no clinical trials have been conducted. This represents a major gap given the compound's extreme potency.

Known and theoretical concerns:

• Cancer risk: The HGF/c-Met pathway is one of the most well-characterized oncogenic pathways in cancer biology. c-Met overactivation drives tumor growth, invasion, and metastasis in many cancer types. This is the primary safety concern with Dihexa — its potent c-Met activation could theoretically promote cancer cell growth or accelerate pre-existing cancers.
• Long-lasting structural changes: Dihexa's apparent ability to create lasting structural changes in the brain (synaptogenesis) means that unwanted neurological effects might also be long-lasting. The clinical implications of this are unknown.
• Extreme potency uncertainty: When a compound is orders of magnitude more potent than expected, the margin between effective and excessive doses may be very narrow, increasing risk of overdose-related effects.
• Lack of human toxicology data: Phase I safety studies in humans have not been published, so basic human pharmacokinetics, maximum tolerated dose, and dose-limiting toxicities are unknown.

Given these concerns, Dihexa is considered among the higher-risk research peptides from a safety perspective, despite the promising animal data.

Disclaimer: Dihexa is not approved for human use and has not undergone human safety trials. The following is for educational purposes only, and its use in humans carries uncertain risks.

Administration routes used in animal research:

• Subcutaneous injection: Most animal studies use SC injection; doses in rodent studies typically range from 0.01–1 mg/kg
• Topical/transdermal: Dihexa can penetrate the skin and reach the CNS transcutaneously, and some research protocols use topical application on the inner arm or scalp
• Oral: Some animal studies have used oral gavage; oral bioavailability is uncertain

Anecdotal community protocols typically reference very small doses (100–200 mcg subcutaneously or transdermally) once weekly or less frequently, reflecting an attempt to account for its extraordinary potency. However, these are entirely empirical and lack scientific validation.

The frequency of use is particularly uncertain — given potential long-lasting structural effects, many protocols suggest infrequent administration rather than daily dosing.

Dihexa research is primarily from Washington State University and a small number of collaborating groups:

• Harding/Wright group: The original developers have published foundational studies demonstrating Dihexa's cognitive effects in hippocampal lesion models and its HGF/c-Met mechanism. The potency comparisons to BDNF are drawn from their synaptogenesis assay data.
• Alzheimer's models: Studies using transgenic Alzheimer's mouse models show Dihexa treatment reduces amyloid-associated cognitive impairment, consistent with a synaptogenesis-based mechanism operating independently of amyloid clearance.
• Comparative efficacy: The comparison to BDNF potency is compelling but based on cell culture assays; whether this potency ratio translates to in vivo conditions is uncertain.

Key gaps in the research:

• No human pharmacokinetics or safety data
• No clinical trials initiated for any indication
• The cancer risk from c-Met activation has not been formally assessed in long-term animal studies
• Independent replication of core findings by other research groups is limited
• Optimal dosing regimen (dose, frequency, duration) for human use has never been established

Dihexa represents one of the most intriguing but also most uncertain entries in cognitive peptide research.